Diagnostics 2009: Moving towards personalized medicine

The growth of personalized medicine, which aims to better target treatments to patients through the use of information about an individual’s genes, proteins and environment to prevent, diagnose and treat disease, is changing the healthcare industry and increasing the number of alliances between diagnostic and pharmaceutical businesses. PricewaterhouseCoopers’ new report, Diagnostics 2009: Moving towards personalized medicine, reviews the flurry of deal activity in the past few years in the in vitro diagnostics (IVD) sector and discusses significant events for personalized medicine, a field which is fast rising to prominence in healthcare innovation. Topics covered include M&A and licensing deal activity, regulatory developments on biomarker testing, partnerships with the pharmaceutical industry, significant events beyond deal activity, case studies and key drivers of future revenue growth for personalized medicine diagnostics.